AZELEAD

Good morning and welcome, we are pleased to introduce you to our structure. AZELEAD has developed ZebraScreen and ZebraTox, an innovative methodology for rapid and accurate assessment of the efficacy and toxicity of a drug In the past few years, we have seen a lot of attrition in the development of new drugs, with a failure rate of nearly 84% attributed to the low benefit of efficacy / toxicity. Three therapeutic areas are mainly affected by this decrease:  oncology (failure rate of 29.5%),  neurology (failure rate of 14%),  and infectious diseases (failure rate of 9.5%). Pharmaceutical companies attribute this attrition to transposability between in vitro and in vivo studies, highlighting the need for new predictive models. AZELEAD responds to this need by providing innovative solutions in these key therapeutic areas. The models are developed using zebrafish, a totally transparent fish to visualize in real time the effectiveness of a drug and its side effects on the body. We are at your disposal to study together your needs and best meet your expectations!